Literature DB >> 23006737

Complement activation in pregnancy: too much of a good thing?

Jeffrey S Gilbert, Christopher T Banek, Vern L Katz, Sara A Babcock, Jean F Regal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23006737      PMCID： PMC3508717          DOI： 10.1161/HYPERTENSIONAHA.112.202747

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  10 in total

Review 1.  Pre-eclampsia.

Authors:  Eric A P Steegers; Peter von Dadelszen; Johannes J Duvekot; Robert Pijnenborg
Journal:  Lancet       Date:  2010-07-02       Impact factor: 79.321

2.  Preeclampsia is characterized by placental complement dysregulation.

Authors:  Aletta Buurma; Danielle Cohen; Kimberley Veraar; Dorrith Schonkeren; Frans H Claas; Jan A Bruijn; Kitty W Bloemenkamp; Hans J Baelde
Journal:  Hypertension       Date:  2012-09-24       Impact factor: 10.190

3.  Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes.

Authors:  Anne M Lynch; Ronald S Gibbs; James R Murphy; Patricia C Giclas; Jane E Salmon; V Michael Holers
Journal:  Obstet Gynecol       Date:  2011-01       Impact factor: 7.661

4.  Activation of the complement system in normal pregnancy and preeclampsia.

Authors:  Zoltán Derzsy; Zoltán Prohászka; János Rigó; George Füst; Attila Molvarec
Journal:  Mol Immunol       Date:  2010-02-23       Impact factor: 4.407

5.  Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss.

Authors:  Danielle Cohen; Aletta Buurma; Natascha N Goemaere; Guillermina Girardi; Saskia le Cessie; Sicco Scherjon; Kitty W M Bloemenkamp; Emile de Heer; Jan A Bruijn; Ingeborg M Bajema
Journal:  J Pathol       Date:  2011-06-20       Impact factor: 7.996

6.  Role of complement component C1q in the onset of preeclampsia in mice.

Authors:  Jameel Singh; Abdulwahab Ahmed; Guillermina Girardi
Journal:  Hypertension       Date:  2011-08-22       Impact factor: 10.190

7.  Prepregnancy obesity and complement system activation in early pregnancy and the subsequent development of preeclampsia.

Authors:  Anne M Lynch; Robert H Eckel; James R Murphy; Ronald S Gibbs; Nancy A West; Patricia C Giclas; Jane E Salmon; V Michael Holers
Journal:  Am J Obstet Gynecol       Date:  2012-03-07       Impact factor: 8.661

8.  Targeted inhibition of complement activation prevents features of preeclampsia in mice.

Authors:  Xiaoping Qing; Patricia B Redecha; Melissa A Burmeister; Stephen Tomlinson; Vivette D D'Agati; Robin L Davisson; Jane E Salmon
Journal:  Kidney Int       Date:  2010-10-13       Impact factor: 10.612

9.  Immunohistochemical detection of terminal complement complex and S protein in normal and pre-eclamptic placentae.

Authors:  F Tedesco; O Radillo; G Candussi; A Nazzaro; T E Mollnes; D Pecorari
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

10.  Immunological studies of human placentae: complement components in pre-eclamptic chorionic villi.

Authors:  D Sinha; M Wells; W P Faulk
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330
  10 in total
  3 in total

1.  Differential effects of complement activation products c3a and c5a on cardiovascular function in hypertensive pregnant rats.

Authors:  Kathryn E Lillegard; Alex C Loeks-Johnson; Jonathan W Opacich; Jenna M Peterson; Ashley J Bauer; Barbara J Elmquist; Ronald R Regal; Jeffrey S Gilbert; Jean F Regal
Journal:  J Pharmacol Exp Ther       Date:  2014-08-22       Impact factor: 4.030

Review 2.  TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease.

Authors:  Jae C Chang
Journal:  Thromb J       Date:  2018-08-11

3.  Complement Split Products in Amniotic Fluid in Pregnancies Subsequently Developing Early-Onset Preeclampsia.

Authors:  Manu Banadakoppa; Alex C Vidaeff; Uma Yallampalli; Susan M Ramin; Michael A Belfort; Chandra Yallampalli
Journal:  Dis Markers       Date:  2015-10-18       Impact factor: 3.434
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.